Online inquiry

IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10178MR)

This product GTTS-WQ10178MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Myocardial infarction research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10178MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9867MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ875MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ2539MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ5505MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ2088MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ8022MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ12782MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ3234MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW